Danofloxacin API Manufacturers & Suppliers

Danofloxacin is a fluoroquinolone antibiotic primarily utilized in veterinary medicine. It belongs to the chemical class of quinoline carboxylic acids, characterized by a quinoline ring structure substituted with at least one carboxyl group. The compound functions as an anti-infective agent targeting bacterial pathogens in animals.

Although specific clinical indications for danofloxacin are not detailed here, fluoroquinolones are generally employed for treating bacterial infections in a variety of animal species. Danofloxacin is approved for veterinary use in certain regions and is categorized as an experimental or veterinary-approved agent depending on local regulatory frameworks.

The pharmacological action of danofloxacin is consistent with others in the fluoroquinolone class. These agents exert bactericidal effects by inhibiting bacterial DNA gyrase and topoisomerase IV enzymes. This inhibition disrupts critical processes of DNA replication, transcription, and repair, ultimately leading to bacterial cell death. The drug is active against a broad spectrum of gram-negative and some gram-positive bacteria, although specific susceptibility profiles may vary by pathogen and animal species.

Key absorption, distribution, metabolism, and excretion (ADME) properties of danofloxacin have been studied in target animals, demonstrating adequate systemic bioavailability following oral or parenteral administration. The compound is known to achieve effective tissue penetration, supporting its use in systemic infections. Metabolism is limited, with primary elimination occurring via renal excretion of unchanged drug.

From a safety standpoint, fluoroquinolones, including danofloxacin, may carry risks of adverse effects such as cartilage development inhibition in juvenile animals, central nervous system disturbances, and potential for resistance development with improper use. Veterinary formulations undergo safety assessments appropriate to intended species.

Notable brand names for danofloxacin formulations vary by market. Due to the specificity of veterinary usage, product availability is typically controlled to ensure proper prescribing and administration.

When sourcing danofloxacin API, it is critical to verify compliance with veterinary pharmaceutical standards, including purity, residual solvent limits, and absence of contaminants. Procurement from manufacturers adhering to Good Manufacturing Practices (GMP) and holding relevant regulatory certifications ensures API quality suitable for incorporation into veterinary medicinal products.